Hugel, Inc.

KOSDAQ:A145020 Stock Report

Market Cap: ₩3.0t

Hugel Past Earnings Performance

Past criteria checks 5/6

Hugel has been growing earnings at an average annual rate of 20.4%, while the Biotechs industry saw earnings declining at 1.1% annually. Revenues have been growing at an average rate of 12.6% per year. Hugel's return on equity is 14%, and it has net margins of 30.8%.

Key information

20.4%

Earnings growth rate

23.6%

EPS growth rate

Biotechs Industry Growth11.7%
Revenue growth rate12.6%
Return on equity14.0%
Net Margin30.8%
Last Earnings Update30 Sep 2024

Recent past performance updates

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Mar 29
Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 29
Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Recent updates

Hugel, Inc.'s (KOSDAQ:145020) Intrinsic Value Is Potentially 94% Above Its Share Price

Dec 15
Hugel, Inc.'s (KOSDAQ:145020) Intrinsic Value Is Potentially 94% Above Its Share Price

Hugel (KOSDAQ:145020) Has A Rock Solid Balance Sheet

Oct 19
Hugel (KOSDAQ:145020) Has A Rock Solid Balance Sheet

An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

Sep 13
An Intrinsic Calculation For Hugel, Inc. (KOSDAQ:145020) Suggests It's 39% Undervalued

There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Aug 09
There's Reason For Concern Over Hugel, Inc.'s (KOSDAQ:145020) Price

Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)

Jun 10
Estimating The Intrinsic Value Of Hugel, Inc. (KOSDAQ:145020)

Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly

Apr 19
Hugel (KOSDAQ:145020) Seems To Use Debt Rather Sparingly

Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Mar 29
Hugel's (KOSDAQ:145020) Performance Is Even Better Than Its Earnings Suggest

Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings

Mar 05
Hugel, Inc.'s (KOSDAQ:145020) 25% Price Boost Is Out Of Tune With Earnings

Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)

Mar 04
Calculating The Fair Value Of Hugel, Inc. (KOSDAQ:145020)

Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

Mar 19
Are Hugel, Inc.'s (KOSDAQ:145020) Mixed Financials Driving The Negative Sentiment?

What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

Feb 25
What Is The Ownership Structure Like For Hugel, Inc. (KOSDAQ:145020)?

Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

Feb 04
Does Hugel (KOSDAQ:145020) Have A Healthy Balance Sheet?

The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Jan 17
The Hugel (KOSDAQ:145020) Share Price Has Gained 197%, So Why Not Pay It Some Attention?

Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Dec 29
Does Hugel's (KOSDAQ:145020) Statutory Profit Adequately Reflect Its Underlying Profit?

Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

Dec 14
Does This Valuation Of Hugel, Inc. (KOSDAQ:145020) Imply Investors Are Overpaying?

How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Nov 24
How Many Hugel, Inc. (KOSDAQ:145020) Shares Do Institutions Own?

Revenue & Expenses Breakdown

How Hugel makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A145020 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24363,785112,044104,2628,438
30 Jun 24343,494111,174106,7548,952
31 Mar 24329,62697,506111,9309,927
31 Dec 23319,70093,076109,47011,015
30 Sep 23316,24578,490112,43414,330
30 Jun 23302,10566,435111,26614,722
31 Mar 23284,41259,834104,16514,902
31 Dec 22281,67560,55894,51415,078
30 Sep 22253,83862,66582,95913,833
30 Jun 22235,49955,51172,12613,284
31 Mar 22229,67954,98165,36012,366
31 Dec 21231,85956,50661,67512,624
30 Sep 21241,63464,58259,82311,853
30 Jun 21243,36954,22256,15114,060
31 Mar 21233,60454,61551,13515,879
31 Dec 20211,03841,99249,32615,741
30 Sep 20197,62939,72850,50714,950
30 Jun 20194,69939,91054,20312,849
31 Mar 20196,70736,81557,97011,034
31 Dec 19204,56844,61261,52010,226
30 Sep 19209,36047,99366,02210,433
30 Jun 19193,15460,76368,3609,514
31 Mar 19185,73264,10465,7528,823
31 Dec 18182,39269,73660,9647,750
30 Sep 18173,68875,55249,9816,930
30 Jun 18180,32269,98539,3746,653
31 Mar 18183,61373,91834,2027,038
31 Dec 17182,08572,82730,9336,922
30 Sep 17169,77867,66526,9126,878
30 Jun 17161,01163,02226,7185,811
31 Mar 17145,78656,09625,9194,436
31 Dec 16124,18943,27325,1874,065
30 Sep 16108,88336,54023,3503,372
30 Jun 1694,23173,09322,3032,919
31 Mar 1680,09839,21618,7953,884
31 Dec 1565,06633,92916,4253,156
30 Sep 1559,32833,92414,9403,087
30 Jun 1549,887-12,90411,9633,616
31 Dec 1440,35013,15010,6521,942
31 Dec 1329,1707,3077,1752,220

Quality Earnings: A145020 has high quality earnings.

Growing Profit Margin: A145020's current net profit margins (30.8%) are higher than last year (24.8%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A145020's earnings have grown significantly by 20.4% per year over the past 5 years.

Accelerating Growth: A145020's earnings growth over the past year (42.7%) exceeds its 5-year average (20.4% per year).

Earnings vs Industry: A145020 earnings growth over the past year (42.7%) exceeded the Biotechs industry 5.8%.

Return on Equity

High ROE: A145020's Return on Equity (14%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 01:32
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hugel, Inc. is covered by 26 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyeryeong KimCGS International
Seohyun LeeCitigroup Inc
Hyonseok KimCLSA